This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag
by Sundeep Ganoria
The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Zacks Equity Research
Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day.
Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study
by Zacks Equity Research
Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.
Annovis (ANVS) AD Study to Continue as Planned, Shares Rise
by Zacks Equity Research
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any additional patients.
Wall Street Analysts See a 25.44% Upside in Biogen Inc. (BIIB): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Biogen Inc. (BIIB) points to a 25.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Inc. (BIIB) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Biogen Inc. (BIIB) closed at $264.21, indicating a +0.36% shift from the previous trading day.
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B
by Zacks Equity Research
Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $252.86 in the latest trading session, marking a -1.61% move from the prior day.
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
by Zacks Equity Research
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.
Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%
by Zacks Equity Research
Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.
Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar
by Zacks Equity Research
Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $255.02, marking a -1.03% move from the previous day.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $253.30, marking a -0.58% move from the previous day.
Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $258.44, marking a -0.19% move from the previous day.
Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar
by Zacks Equity Research
Novartis (NVS) announces an agreement with Samsung Bioepis for exclusive rights to commercialize the biosimilar of Stelara in Europe and North America. The company discontinues the development of GT005 in geographic atrophy.
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
by Zacks Equity Research
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group
by Zacks Equity Research
Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group are part of the Zacks top Analyst Blog.
Top Analyst Reports for Humana, Cintas & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corporation (CTAS) and Biogen Inc. (BIIB).
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
by Zacks Equity Research
Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.
Should BNY Mellon US Mid Cap Core Equity ETF (BKMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for BKMC
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $263.72 in the latest trading session, marking a -0.97% move from the prior day.
Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.